Second and third line treatment in non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, and the advances in second and third line treatment have led to prognostic improvements in the latest years. Besides the two cytotoxic agents, docetaxel and pemetrexed, approved in NSCLC second line treatment, a new class of drugs against specific molecular targets seems to be an alternative to conventional treatment. Many trials are ongoing to assess the activity of new drugs, alone or in association, and new combinations of third-generation chemotherapeutic agents.
Favaretto
Adolfo
A
U.O. Oncologia Medica 2, Istituto Oncologico Veneto IOV IRCCS, Via Gattamelata 64, 35128 Padova, Italy. adolfo.favaretto@sanita.padova.it
Pasello
Giulia
G
Magro
Cristina
C
Schettino
Clorinda
C
Gridelli
Cesare
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016879:Salvage Therapy
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases